Baseline characteristics of patients in the LDC and SDC cohorts
| Characteristic . | LDC* . | SDC . | Total . | P† . |
|---|---|---|---|---|
| Sex | 83 | 100 | 183 | .355 |
| Male | 45 (54.2) | 61 (61.0) | 106 (57.9) | |
| Female | 38 (45.8) | 39 (39.0) | 77 (42.1) | |
| Age, y | 83 | 100 | 183 | .424 |
| Median | 6.1 | 7.5 | 6.8 | |
| Range | 0.8-14.2 | 0.3-13.8 | 0.3-14.2 | |
| WBC count, × 109/L | 83 | 100 | 183 | .001 |
| Median | 12.48 | 27.67 | 17.9 | |
| Range | 1.33-283.41 | 0.42-606 | 0.42-606 | |
| FAB subtype | 83 | 100 | 183 | .058 |
| M1/M2 | 38 (45.8) | 43 (43.0) | 81 (44.3) | |
| M4/M5 | 31 (37.4) | 49 (49.0) | 80 (43.7) | |
| M6 | 0 | 1 (1.0) | 1 (0.5) | |
| M7 | 7 (8.4) | 1 (1.0) | 8 (4.4) | |
| Unclassified | 7 (8.4) | 6 (6.0) | 13 (7.1) | |
| Gene rearrangements | 83 | 100 | 183 | .432 |
| RUNX1–RUNX1T1 | 33 (39.8) | 35 (35.0) | 68 (37.1) | |
| KMT2Ar | 11 (13.2) | 14 (14.0) | 25 (13.7) | |
| CBF/MYH11 | 6 (7.2) | 15 (15.0) | 21 (11.5) | |
| BCR–ABL | 0 | 1 (1.0) | 1 (0.5) | |
| Negative | 33 (39.8) | 35 (35.0) | 68 (37.2) | |
| Gene mutations | 76 | 92 | 168 | .168 |
| C-KIT | 19 (25.0) | 23 (25.0) | 42 (25.0) | |
| CEBPα biallelic mutation | 6(7.9) | 3(3.3) | 9(5.4) | |
| FLT3-ITD | 4(5.3) | 12(13.0) | 16(9.5) | |
| WT1 | 4(5.3) | 0 | 4(2.4) | |
| NPM1 | 2 (2.6) | 1(1.1) | 3 (1.8) | |
| PTPN11 | 2 (2.6) | 2 (2.2) | 4 (2.4) | |
| Other | 6(7.9) | 6(6.5) | 12(7.1) | |
| Negative | 33 (43.4) | 45 (48.9) | 78 (46.4) | |
| Provisional risk group | 83 | 100 | 183 | .035 |
| Low | 10 (12.0) | 15 (15.0) | 25 (13.7) | |
| Intermediate | 56 (67.5) | 49 (49.0) | 105 (57.3) | |
| High | 17 (20.5) | 36 (36.0) | 53 (29.0) | |
| Definitive risk group | 77 | 95 | 172 | .016 |
| Low | 10 (13.0) | 15 (15.8) | 25 (14.5) | |
| Intermediate | 51 (66.2) | 43 (45.3) | 94 (54.7) | |
| High | 16 (20.8) | 37 (38.9) | 53 (30.8) |
| Characteristic . | LDC* . | SDC . | Total . | P† . |
|---|---|---|---|---|
| Sex | 83 | 100 | 183 | .355 |
| Male | 45 (54.2) | 61 (61.0) | 106 (57.9) | |
| Female | 38 (45.8) | 39 (39.0) | 77 (42.1) | |
| Age, y | 83 | 100 | 183 | .424 |
| Median | 6.1 | 7.5 | 6.8 | |
| Range | 0.8-14.2 | 0.3-13.8 | 0.3-14.2 | |
| WBC count, × 109/L | 83 | 100 | 183 | .001 |
| Median | 12.48 | 27.67 | 17.9 | |
| Range | 1.33-283.41 | 0.42-606 | 0.42-606 | |
| FAB subtype | 83 | 100 | 183 | .058 |
| M1/M2 | 38 (45.8) | 43 (43.0) | 81 (44.3) | |
| M4/M5 | 31 (37.4) | 49 (49.0) | 80 (43.7) | |
| M6 | 0 | 1 (1.0) | 1 (0.5) | |
| M7 | 7 (8.4) | 1 (1.0) | 8 (4.4) | |
| Unclassified | 7 (8.4) | 6 (6.0) | 13 (7.1) | |
| Gene rearrangements | 83 | 100 | 183 | .432 |
| RUNX1–RUNX1T1 | 33 (39.8) | 35 (35.0) | 68 (37.1) | |
| KMT2Ar | 11 (13.2) | 14 (14.0) | 25 (13.7) | |
| CBF/MYH11 | 6 (7.2) | 15 (15.0) | 21 (11.5) | |
| BCR–ABL | 0 | 1 (1.0) | 1 (0.5) | |
| Negative | 33 (39.8) | 35 (35.0) | 68 (37.2) | |
| Gene mutations | 76 | 92 | 168 | .168 |
| C-KIT | 19 (25.0) | 23 (25.0) | 42 (25.0) | |
| CEBPα biallelic mutation | 6(7.9) | 3(3.3) | 9(5.4) | |
| FLT3-ITD | 4(5.3) | 12(13.0) | 16(9.5) | |
| WT1 | 4(5.3) | 0 | 4(2.4) | |
| NPM1 | 2 (2.6) | 1(1.1) | 3 (1.8) | |
| PTPN11 | 2 (2.6) | 2 (2.2) | 4 (2.4) | |
| Other | 6(7.9) | 6(6.5) | 12(7.1) | |
| Negative | 33 (43.4) | 45 (48.9) | 78 (46.4) | |
| Provisional risk group | 83 | 100 | 183 | .035 |
| Low | 10 (12.0) | 15 (15.0) | 25 (13.7) | |
| Intermediate | 56 (67.5) | 49 (49.0) | 105 (57.3) | |
| High | 17 (20.5) | 36 (36.0) | 53 (29.0) | |
| Definitive risk group | 77 | 95 | 172 | .016 |
| Low | 10 (13.0) | 15 (15.8) | 25 (14.5) | |
| Intermediate | 51 (66.2) | 43 (45.3) | 94 (54.7) | |
| High | 16 (20.8) | 37 (38.9) | 53 (30.8) |
Data are presented as n (%), unless otherwise specified.
NR, no remission.
Selected data on 46 study patients have been previously reported.20
The Mann-Whitney U test was used for continuous variables; Fisher’s exact test was used for categorical variables with 2×2 charts; Monte Carlo analysis was used for categorical variables with N×2 charts.